Makoto Tahara

36PUBLICATIONS
165CO-AUTHORS
Solid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Microbial taxonomyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Aug 03, 2026
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

|Jul 31, 2026
Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

|Jun 26, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

|Mar 26, 2026
Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.

Naomi Kiyota, Makoto Tahara, Hiroo Imai

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

Pageof 6

Frequent Collaborators

8 joint publications

Naomi Kiyota

8 joint publications

Kevin J Harrington

7 joint publications

Robert I Haddad

5 joint publications

Amanda Psyrri